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perspective was considered. We considered the following cost components: 
human resources, training, infrastructure, equipment and office supplies, trans-
portation, personal protective equipment (PPE), field and laboratory equipment, 
insecticides and social mobilization, considering capital and recurrent costs. 
Capital costs were estimated for both transmission periods combined. Results: 
The total and monthly recurring costs of the PMCD during the epidemic period 
was R$8.307.590 (US$4.988.345) and R$1.400.819 (US$841.131) respectively; and in 
the endemic period was R$ 5.848.678 (US$ 3.511.876) and R$950.619 (US$570.805), 
with human resources being responsible for the majority of costs in both peri-
ods (83 and 86%, respectively). Capital costs for both periods were R$683,315 
(U.S.$410,301), with a high cost share for transportation (80%) and infrastructure 
(13%) components. The Municipal health department was responsible for 83% 
of total costs, followed by state (13%), and federal (3%) levels. ConClusions: 
Although the estimated costs of the PMCD is under-estimated, we demonstrate a 
significant incremental costs (R$3.050,211 or U.S.$1.831.518) during the epidemic 
period. Our results can provide inputs for cost-effectiveness studies of dengue 
vaccines, which are important to support decision making regarding its introduc-
tion into public health programs.
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THe ecology of Medical care in Poor SeTTingS: Self rePorTed HealTH 
care UTilizaTion in SanTiago del eSTero, argenTina
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objeCtives: Health services utilization in poor provinces in Argentina is poorly 
known, due to data poor environments. We utilized a population based health care 
survey to analyzed the ecology of medical care, and to estimate self reported health 
care services utilization (SRHCU) patterns among adults (≥ 18 years old). Methods: 
A health Survey was performed, with probabilistic, stratified, polyetapic sampling, 
adding health utilization questions to the National Risk Factor Survey of Argentina 
(ENFR 2009) questionnaire. We obtained SRHCU stratified as ambulatory visits, 
emergency, hospitalizations, stratified into age, sex, rural, urban, health status and 
prior health problem. Analysis was performed with SPSS 17, 95%CI for single pro-
portions was obtained. Results: Among 2064 persons that responded de survey, 
78,9% were urban-21,1% rural, 41,2% males, mean age was 39,9% (SD 15,8) years 
old, age range 18-93. The General Health Status was regular or bad (16,08%) (95%CI 
14,5-17,7%). Likert scale of health status provided Mean = 86,65 (SD 104,35); Median 
80 (25P = 70; 75P = 90). Acute illness events in prior 4 weeks occurred in 24,8% (95%CI 
22,9-26,7%). 70,4% had an ambulatory visit in the prior 6 months (95%CI 68,4-72,4%), 
while, in prior month 17,0% (95%CI 15,4-18,7%) consulted a physician office [gen-
eralist 10,36% (95%CI 9,1-11,7%) and 6,7% specialist (95%CI 5,6-7,8%)]. Office visits 
rate was 261 per 100 persons per year [increased with age 65+ (305), regular or bad 
health (458), and rurality (289), decreased for males (197)]. Emergency visits occurred 
in 106 persons (5,1%) (95%CI 4,18-6,09%); Hospitalization was 10,6% during prior 
year (95%CI 9,3-11,9%), 78% admitted once and 20% readmitted to the hospital in 
the same period. ConClusions: Results provide an estimate of SRHCU data, and 
show lower ambulatory and emergency visit rates, while hospitalization admis-
sions and readmissions is similar to other ecology of medical care studies in other 
areas of the world.
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objeCtivos: Revisar la respuesta que aportan diferentes analistas a la pre-
gunta: ¿qué es lo que obtenemos del sistema sanitario (SS)? MetodologíAs: 
Se han revisado las propuestas de la OMS, la OCDE y el enfoque del NHS bri-
tánico. También las aproximaciones de investigadores como D. Cutler y J. Puig-
Junoy. ResultAdos: La OMS combina diferentes dimensiones: resultados en 
salud, equidad, equilibrio financiero y respuesta del sistema sanitario, obteniendo 
un indicador de medida absoluta y proponiendo dos índices relativos de efi-
ciencia: uno relacionado con el nivel de esperanza de vida ajustada por inca-
pacidad y otro que valora la eficiencia del SS en general. En la OCDE consideran 
que debe adjudicarse la prioridad a la medición de la relación costo-efectividad. 
Actualmente sus esfuerzos se orientan a la búsqueda de indicadores de calidad. 
El tercer enfoque estudia la variación de la productividad en el seno del NHS, 
definida como el output obtenido en relación con los inputs utilizados. Se con-
sidera que la efectividad no puede determinarse dado el grado de incertidumbre 
con respecto a los efectos específicos del SS y aboga por ponderar los resultados 
con medidas de calidad. Cutler et al obtuvieron un valor de $19.900 como coste 
por año de vida ganado (C/AVG) en el período 1960-2000 en EEUU, asumiendo que 
el SS es el responsable de la mitad del resultado. Puig-Junoy y Merino-Castelló 
estudiaron para el período 1960-2001 la productividad marginal del gasto sani-
tario en España y obtuvieron un C/AVG entre 10.045 y 12.937. ConClusiones: 
No hay consenso en cuanto al estudio de la efectividad del sistema sanitario. 
La indeterminación que supone la influencia de elementos ajenos al mismo en 
el resultado final supone un inconveniente importante. La incorporación de la 
calidad puede ayudar a superar, en parte, este problema.
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objeCtivos: Determinar las diferencias del trabajo en equipo en salas de cirugía 
entre un hospital privado y uno público de Bogotá, D.C. MetodologíAs: Estudio 
observacional analítico. Muestra: n= 90 equipos de cirugía, 49 de hospital privado 
(54%) y 41 de hospital público (46%). Criterios de inclusión: Equipos de cirugía 
general de hospitales de tercer nivel de complejidad de la ciudad de Bogotá, D.C. 
and Prevention (NCC MERP) severity scale. Results: When the list of triggers was 
used for the review of AE case reports, 61 triggers were identified in 167 (50.2%) 
cases. Transfusion / use of blood products (15%), infection of any kind (6.9%) were 
the commonly noted triggers in the critical care module. In the surgical module, 
return to surgery (6%) and occurrence of any post surgical complication (6%) were 
predominantly noted. In the medication module, repeated request for lab inves-
tigations (13.2%), use of laxatives (13.2%), pyrexia (10.8%), use of nebuliser/steam 
inhalation (7.5%), use of analgesics (6.6%) and anti-emetics (5.7%) were commonly 
noted. When the harm was studied category E was 24.9% followed by Category F- 
13.8%. ConClusions: The developed trigger list was able to flag 167 case profiles 
with potential adverse events. This tool has potential application in reviewing the 
cases for adverse events.
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objeCtives: To identify the most appropriate dosage regimen of pralidoxime that 
can be recommended for the management of OP poisoning. Methods: An open 
labeled cross-sectional, nonrandomized observational study was carried out in 
emergency wards of tertiary care hospital. A total of 256 OP poisoned patients were 
admitted between 2009 to 2013. The basic demographical, clinical characteristics 
and severity were assessed at admission. Based on the pralidoxime dosage regi-
men patients were categorized into 4 different groups viz. control, intermittent, 
500mg/ hour, 1g/ hour groups. The clinical outcome analyzed in terms of hospi-
talization days, ventilatory days, total atropine required, and incidence of inter-
mediate syndrome and outcome were assessed for comparison with pralidoxime 
regimen Results: The results showed that majority of OP poisoned patients were 
in the age group of 21-30 years, and males predominated the females (2.3:1). Clinical 
Severity assessment of these patients showed that most of them had moderate to 
high severity. Outcome analysis showed that patients of continuous infusion of 
pralidoxime had significantly improved recovery rate with least sequel and fatal-
ity rate. The incidence of intermediate syndrome, number of ventilation days, total 
atropine requirement, number of hospitalization days and mortality rate signifi-
cantly reduced in continuous infusion group. ConClusions: Continuous infusion 
of pralidoxime at 500 mg/hour resulted in significantly better clinical outcome than 
other dosing regimens and not associated with adverse derug reactions.
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Rodrigues T., Izmirlieva M., Ando G.
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objeCtives: To ascertain if the Brazilian HTA body CONITEC, which replaced CITEC 
in December 2011, is delivering on Ministry of Health (MoH) promises of transpar-
ency and set assessment timelines whilst adopting mandatory evidence require-
ments for new biologic drug funding decisions via the Unified Healthcare System 
(SUS). Methods: Secondary research based on CONITEC’s final reimbursement 
recommendation reports, evaluating existing and sponsor submitted data. These 
reports include deliberations from a plenary assembly of representatives from the 
MoH, drug regulator ANVISA and supplementary health regulator ANS, as well as 
public consultation contributions. Results: CONITEC has delivered on transpar-
ency with publications of the rationale behind each of its recommendations, thus 
enabling pharmaceutical firms to understand how to respond. The 180 day initial 
analysis phase deadline is being met but evaluation of the implementation phase 
timeline is premature. Out of the final recommendations published to date for bio-
logics, about 40% correspond to a funding rejection. Biologic medicines have been 
denied funding from psoriasis to wet AMD due to lack of cost-effectiveness as well 
as efficacy and safety studies of short duration and small patient populations. The 
rejection of everolimus for a rare brain tumour shows that orphan drugs are not 
being treated differently. Positive endorsements of biologics from breast cancer to 
rheumatoid arthritis come with recommendations of significant price cuts and crea-
tion of clinical guidelines. ConClusions: Manufacturers are struggling to adjust to 
evidence requirements needed in supporting funding applications for new biologics, 
including orphan drugs. Transparency is evident in CONITEC’s analysis phase but is 
absent after a positive recommendation, when the MoH ascertains how the medi-
cine will be offered by SUS. Nonetheless, this is an advance compared to the CITEC 
process, whereby decisions were not made public and there were no clear timelines.
HealTH care USe & Policy STUdieS – Health care research & education
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The burden of dengue is significant in Brazil. Between 2002 and 2010 approxi-
mately four million probable dengue cases were reported, with significant epi-
demics in 2002, 2008 and 2010. It is expected that a dengue vaccine, currently 
under phase 3 clinical trials, will reduce the number of cases, costs of the disease 
and costs of dengue prevention and control programs, in particular during epi-
demic peaks. objeCtives: Estimate the costs of dengue control program (PMCD) 
in the municipality of Goiânia-GO, Brazil. Methods: We conducted a retrospec-
tive analysis, considering epidemic (October/2009-April/2010), and endemic (May-
September/2010) periods of dengue transmission. The public health care system 
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cos. ConClusiones: Es factible implementar los IMA en 48-72 hs, para responder 
a consultas puntuales acotadas. El perfil fue diferente al de los informes de ETS 
tradicionales. Los IMA más solicitados fueron aquellos relacionados con tecnologías 
terapéuticas, siendo el área oncológica la más frecuente.
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objeCtives: Health technology assessment in Latin America has been relatively 
more mature than other similarly developed health systems. This research explores 
the trends of development of HTA in the region to understand similarities to the 
European HTA model. It further looks at relevance of having such a model in Latin 
America, the relevance of the complexity of the methodologies and utilities used 
and finally, the implications of these trends. Methods: The study was conducted 
in Brazil, Mexico, Argentina and Columbia. Opinions of 18 stakeholders were col-
lected via telephone interviews. Respondents included senior clinical oncologists(3), 
academics(4), policy advisors(2), senior bureaucrats in the health ministries(3), senior 
members of HTA bodies(4) and senior executives from manufacturers(2). A scoring 
system was devised to plot the level of complexity and maturity of the HTA systems 
/ agencies both in Latin America and then comparing it with scores of a similar 
study across Europe and Australia. The responses around the relevance of the model 
and implications were analysed qualitatively adding perspective from the author’s 
experience in these countries. Results: The level of maturity of HTA processes in 
all the countries studied was seen to be generally high. The level of association with 
reimbursement processes was seen to vary. There was a split on the relevance of the 
European model to the Latin American context. Majority of the academics (n= 3/4) and 
members of HTA bodies (n= 2/4) felt that following highly complex European models 
was a necessary natural progression to the HTA development curve. This was not 
the observation with the rest of the stakeholders. ConClusions: There is thought 
to be a trend where there is a push by academics and HTA-related professionals 
towards making it similar to the European model, and thus increasingly complex. 
Greater international attention can be a reason, although it must be further explored.
HealTH care USe & Policy STUdieS – Patient registries & Post-Marketing 
Studies
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objeCtives: Establishing an active postmarketing safety surveillance and analysis 
system, used by health professionals, regulatory bodies and sponsors. Methods: 
The solution consists in making available to the entire community a set of online 
tools aimed to the data collection and analysis on innovative drugs. The introduc-
tion of online integrated environments ensures the appropriate use of drugs, help to 
monitor drug consumption and related costs and improves the real-time reporting 
of suspected adverse drug events. The surveillance system collects patients data in a 
common IT infrastructure within the same network. For 24 antineoplastic drugs the 
system provides also automatic procedures to manage the ‘risk sharing’ & ‘payment 
by result’ approach, that foresees partial or total refund of the cost sustained by 
the hospital pharmacy for the drug in case of progressive disease or unacceptable 
toxicity. Results: This presentation will illustrate the Cineca methodological IT 
approach used also by the Italian National Medicines Agency. The system has been 
used for 70 innovative drugs from eleven different drugs categories: antineoplastic, 
antidiabetics, neurological, dermatological, antiasmatics, ophtalmologic, antireu-
matics and others. More than 500.000 patients were registered by more than 900 
health structures in a timeframe of 7 years. ConClusions: The introduction of 
an online integrated environments ensures a more appropriate drug usage, help to 
monitor drug consumption and related costs and improves the real-time reporting 
of suspected adverse drug events.
HealTH care USe & Policy STUdieS – Population Health
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objeCtives: Chile carried out a health care system reform in 2005 aimed at reduc-
ing health and health care inequities. This study assessed whether household 
income-related inequality in adult self-reported health status (SRHS) was reduced 
after this reform. Methods: Before and after study design using the 2000 and 2009 
CASEN surveys (252 748 and 246 924 participants, respectively) we compared the 
Erreygers concentration index (CI) for SRHS (binary variable: poor= 0, fair/good= 1) 
between these two years. Factors associated with good health were explored using 
weighted logistic regression models. Decomposition analysis of the CIs by “legiti-
mate” (age, sex, marital status, number of household members) and “illegitimate” 
(income, ethnicity, rural/urban, education, occupation, type of health care provision) 
factors was conducted. Results: Results indicated that there was a significant 
concentration of fair/good SRHS favoring the rich people in Chile in both years 
(Erreygers corrected CI for bounded binary variables was 0.165 [Standard Error 0.007] 
in 2000 and 0.053 [0.002] in 2009). We standardized the 2000 and 2009 CIs to assess 
horizontal inequity and decomposed them into “legitimate” factors such as age 
and sex and “illegitimate” factors, mostly socioeconomic conditions. Despite the 
fact that the CIs are not directly comparable between 2000 and 2009, our findings 
suggest that the CI might have decreased after the reform, but good SRHS continued 
Procedimiento: Los datos usados en este estudio hacen parte de la validación del 
instrumento OTAS (Observational Teamwork Assessment for Surgery) en Colombia. 
Una observadora experta en el OTAS ingresó a las salas de cirugía y registró los 
puntajes otorgados a cada subequipo (anestesiólogos, cirujanos, enfermeros e 
instrumentadores quirúrgicos) en cinco comportamientos (comunicación, coordi-
nación, cooperación, liderazgo y conciencia situacional) para las tres fases quirúr-
gicas (pre, intra y post operatorio). Se aplicó la prueba U de Mann-Whitney, se hizo 
la corrección de Bonferroni para el alfa rechazando la hipótesis nula cuando el 
alfa era igual o menor a 0,004, manteniendo así un margen de error para el estudio 
de 5%. ResultAdos: Se encontró que los puntajes obtenidos en el OTAS fueron 
diferentes en la institución privada comparada con la pública (Z= 4,77; p= 0,0000), 
al realizar comparaciones discriminadas se encontraron diferencias significativas 
en los subequipos de anestesiología (Z= 12,17; p= 0,0000), en los comportamientos 
de liderazgo (Z= 3,56; p= 0,0004) y conciencia situacional (Z= 3,20; p= 0,001) y en las 
fases pre quirúrgica (Z= 4,41; p= 0,0000) y post quirúrgica (Z= 4,20; p= 0,0000), en 
todos estos casos los puntajes fueron mayores en los equipos de la institución 
privada. ConClusiones: Teniendo en cuenta el diseño los resultados no pueden 
ser generalizados. Los hallazgos sugieren una diferencia en algunas habilidades 
no técnicas e interacción en los equipos de salud según el tipo de institución, esto 
puede estar relacionado con cumplimiento de protocolos y mayor control de calidad 
implementados en la institución privada.
HealTH care USe & Policy STUdieS – Health Technology assessment 
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bACkgRound: The application of Health Technology Assessment (HTA) and 
Pharmacoeconomics (PE) into real health policies in selected European countries 
(Austria, Bulgaria, Croatia, Czech Republic, Germany, Hungary, Latvia, Poland, 
Romania, Serbia, Slovakia, Slovenia, UK) was analyzed based on the outputs from 
the conference “Optimalization of Methods of PE and HTA: Importance for National 
Health Policy and Cross-Border Cooperation” (Slovakia, 10/2012). objeCtives: The 
objective of the paper was to compare the systems and to find the most transpar-
ent one based on the pre-defined criteria. Methods: The primary method used 
for the analysis was structured evaluation of the outputs from the conference. 
The other relevant information resulted from the systematic review of PUBMED, 
EMBASE and CENTRAL in years 2011-2012 extended to official websites of public 
health institutions and officially published data with the objective to select all 
papers on HTA/Pharmacoeconomics related to selected European countries. We 
evaluated 9 characteristics relevant for the decision-making process: legislative 
background, implementation, binding force, institutionalization, qualified personal 
resources availability, existed methodology/guidelines, clarity of the process, patient 
involvement in the process, and respecting the deadline of 180 days for issuing a 
decision. Results: Resulting from the analysis, of selected countries, the UK was 
shown to have the most transparent system. Germany and Austria ranked second. 
Hungary and Poland ranked third, followed by Slovakia. The least transparent sys-
tem was found in Bulgaria and Romania. ConClusions: One of the criteria was 
qualified personal resources availability that immediately discriminate systems 
in smaller central and eastern European countries. This should result in develop-
ing tailored approaches rather than copying technocratic “western” systems. The 
system prepared in Romania based on multiple criteria decision analysis principle 
could be regarded as a positive example.
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objeCtivos: Si bien la utilización de Evaluación de Tecnologías (ETS) para la toma 
de decisiones es cada vez más utilizada en Argentina, es habitual la disociación 
entre el tiempo para la toma de decisiones cotidianas y el que demanda la reali-
zación de informes tradicionales. El Instituto de Efectividad Clínica y Sanitaria 
(IECS), una de las principales agencias de ETS de Latinoamérica, provee informes a 
instituciones públicas, de seguridad social y seguros privados. Se diseñó un nuevo 
tipo de documento orientado a responder una consulta puntual (motivada por 
un caso real), de respuesta en 48-72 hs, denominado Informe de Mesa de Ayuda 
(IMA). El objetivo es describir la experiencia del primer año y evaluar cuáles son las 
tecnologías más solicitadas como IMA por un grupo de decisores de Argentina y 
Uruguay. MetodologíAs: Descripción y análisis de las bases de datos de IMA reali-
zados por IECS. ResultAdos: Entre enero de 2011 y febrero de 2013 se realizaron 
110 IMA. El 78% de los pedidos correspondieron tecnologías terapéuticas (54% dis-
positivos, 26% procedimientos y 20% radioterapia), 15% a drogas y 7% a tecnologías 
diagnósticas. Esta distribución fue significativamente diferente a la observada 
en los informes de ETS donde se observa que el 52% de los pedidos correspondi-
eron a tecnologías terapéuticas, 34% a drogas y 14% a tecnologías diagnósticas. En 
cuanto a las áreas de interés el 17% de los IMA fueron relacionados con cáncer, 
el 14% con alteraciones neurológicas, el 12% con patologías traumatológicas, 11% 
gastrointestinal, 11% con trastornos urinarios, siguiendo en frecuencia motivos 
quirúrgicos, cardiovasculares, endocrinológicos, trastornos genéticos y oftalmológi-
